Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × EP-100 membrane-disrupting peptide × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Cancer Recurrent 1

Interventions

Cyclophosphamide 650 Cisplatin 607 Gemcitabine 573 Bevacizumab 554 Carboplatin 537 Paclitaxel 535 Docetaxel 512 Radiotherapy 490 Fluorouracil 369 Oxaliplatin 351 Rituximab 333 Doxorubicin 317 Capecitabine 316 Filgrastim 290 Etoposide 290 Irinotecan 280 Dexamethasone 278 Leucovorin 252 Cetuximab 232 pembrolizumab 231 Cytarabine 207 Trastuzumab 201 Erlotinib Hydrochloride 201 Bortezomib 201 Prednisone 197 Vincristine 194 Nivolumab 189 Pemetrexed 177 Methotrexate 175 fludarabine phosphate 173

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡